The British Supreme Court ruled Thursday in favor of Mylan and its Dutch partner Synthon, and canceled all Teva’s Copaxone for 40 mg in the country based on obviousness.
A statement by Mylan believes that the victory in court is yet another milestone for the company to bring high quality generic versions to the MS community around the world.
“This victory is yet another important milestone for Mylan, and this U.K. court decision only further increases Mylan’s confidence in its ability to bring high quality, lower-cost generic versions of Copaxone to the multiple sclerosis community and patients around the world,” Mylan stated.
Over the past eight years, Mylan has managed to overcome four patents litigation protecting Teva’s flagship drug in the U.S. eight Citizen Petitions, injunction proceedings in India, more than 15 regulatory challenges, patent litigations or commercial actions across Europe, and now the litigation in the U.K., in addition to obtaining dismissal of Teva’s suit against the FDA seeking to delay approval of the 20 mg/mL product.
Teva will publish its financial statements for the third quarter on November 2, when analysts predict revenues of $5.63 billion, with a profit of $1.05 per share.